Neural Stem Cell Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Neural stem cell (NSC) therapy represents a promising regenerative approach for neurodegenerative diseases. NSCs are multipotent progenitor cells capable of differentiating into neurons, astrocytes, and oligodendrocytes. They offer potential for replacing lost neurons, supporting surviving cells, and modulating the disease microenvironment.
- Differentiation into region-specific neurons
- Integration into existing neural circuits
- Restoration of neurotransmitter balance
- Secretion of BDNF, GDNF, NGF
- Support for endogenous neurogenesis
- Promotion of synaptic plasticity
- Reduction of neuroinflammation
- Modulation of microglial activation
- Creation of pro-regenerative microenvironment
- Exosome-mediated effects
- Secretion of anti-apoptotic factors
- Enhancement of angiogenesis
- Replacement of dopaminergic neurons
- Potential restoration of motor function
- Several clinical trials completed or ongoing
- fetal-derived and iPSC-derived approaches
- Striatal neuron replacement
- May slow disease progression
- Early-phase clinical trials
- Motor neuron replacement
- Support of surviving motor neurons
- Immunomodulatory effects
- Cholinergic neuron replacement
- Support of hippocampal function
- Currently in preclinical/early clinical stages
¶ Stroke and TBI
- Most advanced clinical applications
- Functional recovery improvements
- Several Phase I/II trials completed
- Human fetal brain tissue-derived
- Well-characterized
- Ethical considerations
- From adult subventricular zone
- Autologous possible
- Limited expansion capacity
- Reprogrammed from somatic cells
- Autologous, patient-specific
- No ethical concerns
- Unlimited differentiation potential
- Allogeneic options
- Tumor risk concerns
| Trial |
Phase |
Condition |
Cell Type |
Status |
| NCT03724136 |
I/II |
PD |
ESC-derived |
Recruiting |
| NCT04802733 |
I |
HD |
Fetal-derived |
Completed |
| NCT03714355 |
I |
ALS |
NSC |
Active |
| NCT03296656 |
I |
Stroke |
NSC |
Completed |
¶ Dosage and Administration
- Intracerebral injection (most common)
- Intrathecal delivery
- Intravenous infusion
- Intranasal administration
- Single or repeated doses
- Immunosuppression often required
- Long-term follow-up essential
- Tumor formation (teratoma)
- Immune rejection
- Intracranial hemorrhage
- Seizures
- Neurological deficits
- Careful cell characterization
- HLA matching
- Controlled differentiation
- Comprehensive monitoring
- Optimization of cell delivery
- Gene-edited NSCs for enhanced survival
- Combination with rehabilitation
- Biomarker development for patient selection
- Scalable manufacturing
The study of Neural Stem Cell Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Barker RA, et al. Human neural stem cells in Parkinson's disease: a review. J Parkinsons Dis. 2021;11(s1):S49-S58.
- Takahashi J. Stem cells and regenerative medicine for Parkinson's disease. Regen Ther. 2020;15:17-22.
- Glass JD, et al. Neural stem cell transplantation in ALS: a Phase I trial. Lancet Neurol. 2020;19(5):384-394.
- Kondziolka D, et al. Neuronal transplantation for stroke. Prog Brain Res. 2021;265:123-145.
- Yuan T, et al. Induced neural stem cells for neurodegenerative disease treatment. Stem Cell Res Ther. 2022;13(1):108.